New pill combo aims to tame aggressive blood cancer
NCT ID NCT05287568
Summary
This early-stage study is testing the safety and best dose of two oral drugs, CC-486 and venetoclax, for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to prior treatment. The main goal is to find the highest dose patients can tolerate without severe side effects. Researchers will also check if the combination helps control the leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CU Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.